bepridil has been researched along with Recrudescence in 12 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter, randomized, placebo-controlled, double-blind trial was conducted with patients with persistent atrial fibrillation (AF) to determine the dose-response effects and safety of bepridil, using every-day transtelephonic monitorings." | 9.14 | Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study). ( Aizawa, Y; Atarashi, H; Fujiki, A; Inoue, H; Ito, M; Katoh, T; Kobayashi, Y; Koretsune, Y; Kumagai, K; Niwano, S; Ogawa, S; Okazaki, O; Okumura, K; Origasa, H; Saku, K; Sato, T; Tanabe, T; Yamashita, T, 2009) |
| "It is unknown whether bepridil improves cardiovascular events in atrial fibrillation (AF) patients, so this study evaluated the clinical outcome in paroxysmal or persistent AF patients receiving bepridil." | 7.77 | Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil. ( Hagiwara, N; Hosaka, F; Naganuma, M; Shiga, T; Shoda, M; Suzuki, A, 2011) |
| "The antiarrhythmic properties of bepridil on ventricular tachycardia (VT) termination and prevention were studied in 16 patients using programmed electrical stimulation techniques." | 7.67 | [Oral and intravenous bepridil in the treatment of recurrent sustained ventricular tachycardias. Electropharmacological study]. ( Cointe, R; Gérard, R; Labrunie, P; Lévy, S; Metge, M; Valeix, P, 1985) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 5.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| "Cilostazol was discontinued 2 days before replacement because of its antiplatelet effects." | 5.40 | Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. ( Ayabe, R; Ebata, Y; Fukui, A; Nakagawa, M; Okada, N; Shinohara, T; Takahashi, N; Yufu, K, 2014) |
| "Bepridil was found to possess electrophysiologic properties common to class I and IV antiarrhythmic agents." | 5.27 | Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing. ( Cointe, R; Faugere, G; Gerard, R; Levy, S; Metge, M; Valeix, B, 1984) |
| "A multicenter, randomized, placebo-controlled, double-blind trial was conducted with patients with persistent atrial fibrillation (AF) to determine the dose-response effects and safety of bepridil, using every-day transtelephonic monitorings." | 5.14 | Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study). ( Aizawa, Y; Atarashi, H; Fujiki, A; Inoue, H; Ito, M; Katoh, T; Kobayashi, Y; Koretsune, Y; Kumagai, K; Niwano, S; Ogawa, S; Okazaki, O; Okumura, K; Origasa, H; Saku, K; Sato, T; Tanabe, T; Yamashita, T, 2009) |
| "It is unknown whether bepridil improves cardiovascular events in atrial fibrillation (AF) patients, so this study evaluated the clinical outcome in paroxysmal or persistent AF patients receiving bepridil." | 3.77 | Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil. ( Hagiwara, N; Hosaka, F; Naganuma, M; Shiga, T; Shoda, M; Suzuki, A, 2011) |
| "The antiarrhythmic properties of bepridil on ventricular tachycardia (VT) termination and prevention were studied in 16 patients using programmed electrical stimulation techniques." | 3.67 | [Oral and intravenous bepridil in the treatment of recurrent sustained ventricular tachycardias. Electropharmacological study]. ( Cointe, R; Gérard, R; Labrunie, P; Lévy, S; Metge, M; Valeix, P, 1985) |
| "The most important arrhythmia is ventricular tachycardia which degenerates to ventricular fibrillation." | 2.43 | [Strategy for cardiac arrhythmias in acute coronary syndrome]. ( Sugi, K, 2006) |
| "The rate of recurrence of atrial fibrillation (AF) and/or atrial tachycardia (AT) within 36 months was compared between the 2 groups." | 1.62 | Effect of preprocedural pharmacologic cardioversion on pulmonary vein isolation in patients with persistent atrial fibrillation. ( Doi, M; Hara, S; Ito, H; Morimoto, T; Morita, H; Okawa, K; Ozaki, M; Sogo, M; Sudo, Y; Takahashi, M; Tsushima, R, 2021) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 1.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| "Cilostazol was discontinued 2 days before replacement because of its antiplatelet effects." | 1.40 | Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. ( Ayabe, R; Ebata, Y; Fukui, A; Nakagawa, M; Okada, N; Shinohara, T; Takahashi, N; Yufu, K, 2014) |
| "Bepridil was found to possess electrophysiologic properties common to class I and IV antiarrhythmic agents." | 1.27 | Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing. ( Cointe, R; Faugere, G; Gerard, R; Levy, S; Metge, M; Valeix, B, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Okawa, K | 1 |
| Hara, S | 1 |
| Morimoto, T | 1 |
| Tsushima, R | 1 |
| Sudo, Y | 1 |
| Sogo, M | 1 |
| Ozaki, M | 1 |
| Takahashi, M | 1 |
| Doi, M | 1 |
| Morita, H | 1 |
| Ito, H | 1 |
| Shinohara, T | 1 |
| Ebata, Y | 1 |
| Ayabe, R | 1 |
| Fukui, A | 1 |
| Okada, N | 1 |
| Yufu, K | 1 |
| Nakagawa, M | 1 |
| Takahashi, N | 1 |
| Kondo, T | 1 |
| Miake, J | 1 |
| Kato, M | 1 |
| Ogura, K | 1 |
| Iitsuka, K | 1 |
| Yamamoto, K | 1 |
| Yamashita, T | 1 |
| Ogawa, S | 1 |
| Sato, T | 1 |
| Aizawa, Y | 1 |
| Atarashi, H | 1 |
| Fujiki, A | 2 |
| Inoue, H | 2 |
| Ito, M | 1 |
| Katoh, T | 1 |
| Kobayashi, Y | 1 |
| Koretsune, Y | 1 |
| Kumagai, K | 1 |
| Niwano, S | 1 |
| Okazaki, O | 1 |
| Okumura, K | 1 |
| Saku, K | 1 |
| Tanabe, T | 1 |
| Origasa, H | 1 |
| Shiga, T | 1 |
| Suzuki, A | 1 |
| Naganuma, M | 1 |
| Hosaka, F | 1 |
| Shoda, M | 1 |
| Hagiwara, N | 1 |
| Okumura, Y | 1 |
| Watanabe, I | 1 |
| Nakai, T | 1 |
| Sugimura, H | 1 |
| Hashimoto, K | 1 |
| Masaki, R | 1 |
| Ohkubo, K | 1 |
| Takagi, Y | 1 |
| Shindo, A | 1 |
| Ozawa, Y | 1 |
| Saito, S | 1 |
| Kanmatsuse, K | 1 |
| Sugi, K | 1 |
| Sakamoto, T | 1 |
| Nishida, K | 1 |
| Mizumaki, K | 1 |
| Levy, S | 2 |
| Cointe, R | 2 |
| Metge, M | 2 |
| Faugere, G | 1 |
| Valeix, B | 1 |
| Gerard, R | 2 |
| Brembilla-Perrot, B | 1 |
| Aliot, E | 1 |
| Clementy, J | 1 |
| Cosnay, P | 1 |
| Djiane, P | 1 |
| Fauchier, JP | 1 |
| Kacet, S | 1 |
| Lellouche, D | 1 |
| Mabo, P | 1 |
| Richard, M | 1 |
| Roy, D | 1 |
| Montigny, M | 1 |
| Klein, GJ | 1 |
| Sharma, AD | 1 |
| Cassidy, D | 1 |
| Labrunie, P | 1 |
| Valeix, P | 1 |
1 review available for bepridil and Recrudescence
| Article | Year |
|---|---|
[Strategy for cardiac arrhythmias in acute coronary syndrome].
Topics: Amiodarone; Angina, Unstable; Anti-Asthmatic Agents; Aprindine; Atrial Fibrillation; Bepridil; Elect | 2006 |
4 trials available for bepridil and Recrudescence
| Article | Year |
|---|---|
Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study).
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Dose-Response Relationship, Drug; Doubl | 2009 |
Recurrence of atrial fibrillation after internal cardioversion of persistent atrial fibrillation: prognostic importance of electrophysiologic parameters.
Topics: Action Potentials; Aged; Atrial Fibrillation; Bepridil; Carbazoles; Carvedilol; Electric Countershoc | 2005 |
Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Bepridil; C-Reactive Protein; Drug The | 2007 |
Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens.
Topics: Administration, Oral; Adult; Aged; Bepridil; Electrophysiology; Female; Humans; Injections, Intraven | 1992 |
7 other studies available for bepridil and Recrudescence
| Article | Year |
|---|---|
Effect of preprocedural pharmacologic cardioversion on pulmonary vein isolation in patients with persistent atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Catheter Ablation; Dose-Response Rela | 2021 |
Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes.
Topics: Adult; Anti-Arrhythmia Agents; Bepridil; Cilostazol; Death, Sudden, Cardiac; Dose-Response Relations | 2014 |
Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Case-Control Studies; Catheter Ab | 2016 |
Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Cardiovascular Diseases; Dose-Response | 2011 |
Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Bepridil; Cardiac Pacing, Artificial; Ele | 1984 |
Electrophysiologic effects and long-term efficacy of bepridil for recurrent supraventricular tachycardias.
Topics: Administration, Oral; Adult; Bepridil; Electrophysiology; Female; Follow-Up Studies; Humans; Injecti | 1987 |
[Oral and intravenous bepridil in the treatment of recurrent sustained ventricular tachycardias. Electropharmacological study].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Bepridil; Dose-Response Relationship, Drug; Drug Evalu | 1985 |